NYSE:MDT - Medtronic Stock Price, News, Headlines & Rumors

Sign in or create an account to add this stock to your watchlist.
$91.10 +0.11 (+0.12 %)
(As of 08/16/2018 04:00 PM ET)
Previous Close$90.99
Today's Range$90.84 - $91.37
52-Week Range$76.41 - $91.50
Volume4.19 million shs
Average Volume4.94 million shs
Market Capitalization$122.46 billion
P/E Ratio19.10
Dividend Yield2.20%
Beta0.94
Medtronic logoMedtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group. The Cardiac and Vascular Group segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation product; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Minimally Invasive Therapies Group segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, hernia mechanical devices, mesh implants, and gynecology products; hardware instruments and mesh fixation device; and gastrointestinal, inhalation therapy, and renal care solutions. The Restorative Therapies Group segment offers products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, colorectal surgeons, urogynecologists, interventional radiologists, and ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems; and therapies for vasculature in and around the brain. The Diabetes Group segment offers insulin pumps and consumables, continuous glucose monitoring systems, and therapy management software. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Receive MDT News and Ratings via Email

Sign-up to receive the latest news and ratings for MDT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:MDT
CUSIP58505510
Phone353-1438-1700

Debt

Debt-to-Equity Ratio0.47
Current Ratio2.28
Quick Ratio1.92

Price-To-Earnings

Trailing P/E Ratio19.10
Forward P/E Ratio17.83
P/E Growth2.46

Sales & Book Value

Annual Sales$29.95 billion
Price / Sales4.11
Cash Flow$6.7985 per share
Price / Cash13.40
Book Value$37.50 per share
Price / Book2.43

Profitability

EPS (Most Recent Fiscal Year)$4.77
Net Income$3.10 billion
Net Margins10.36%
Return on Equity12.84%
Return on Assets6.84%

Miscellaneous

Employees86,000
Outstanding Shares1,351,710,000
Market Cap$122.46 billion

Medtronic (NYSE:MDT) Frequently Asked Questions

What is Medtronic's stock symbol?

Medtronic trades on the New York Stock Exchange (NYSE) under the ticker symbol "MDT."

How often does Medtronic pay dividends? What is the dividend yield for Medtronic?

Medtronic announced a quarterly dividend on Friday, June 22nd. Shareholders of record on Friday, July 6th will be given a dividend of $0.50 per share on Wednesday, July 25th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 2.20%. The ex-dividend date of this dividend is Thursday, July 5th. This is a positive change from Medtronic's previous quarterly dividend of $0.46. View Medtronic's Dividend History.

How will Medtronic's stock buyback program work?

Medtronic declared that its Board of Directors has approved a stock buyback plan on Thursday, October 5th 2017, which authorizes the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to purchase up to 49% of its shares through open market purchases. Shares buyback plans are typically an indication that the company's management believes its shares are undervalued.

How were Medtronic's earnings last quarter?

Medtronic PLC (NYSE:MDT) announced its quarterly earnings data on Thursday, May, 24th. The medical technology company reported $1.42 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.39 by $0.03. The medical technology company had revenue of $8.14 billion for the quarter, compared to the consensus estimate of $8 billion. Medtronic had a net margin of 10.36% and a return on equity of 12.84%. The firm's quarterly revenue was up 2.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.33 earnings per share. View Medtronic's Earnings History.

When is Medtronic's next earnings date?

Medtronic is scheduled to release their next quarterly earnings announcement on Tuesday, August, 21st 2018. View Earnings Estimates for Medtronic.

What guidance has Medtronic issued on next quarter's earnings?

Medtronic updated its FY19 earnings guidance on Thursday, May, 24th. The company provided EPS guidance of $5.10-5.15 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.14.

What price target have analysts set for MDT?

22 equities research analysts have issued 1 year target prices for Medtronic's shares. Their forecasts range from $80.00 to $119.00. On average, they expect Medtronic's stock price to reach $93.2368 in the next twelve months. This suggests a possible upside of 2.3% from the stock's current price. View Analyst Price Targets for Medtronic.

What is the consensus analysts' recommendation for Medtronic?

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medtronic in the last year. There are currently 7 hold ratings, 14 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Medtronic.

What are Wall Street analysts saying about Medtronic stock?

Here are some recent quotes from research analysts about Medtronic stock:
  • 1. According to Zacks Investment Research, "Escalating costs and expenses continue to weigh on Medtronic’s bottom line. The company’s 2019 guidance remains conservative on apprehension of lackluster CVG and MITG performances. However, all major business groups contributed to solid top-line growth at CER, highlighting sustainability across groups and regions, in addition to displaying successful integration and achievement of synergy targets. Also, gradually stabilizing CRHF market holds promise. The receipt of FDA approval for the DBS therapy as adjunctive treatment to reduce partial-onset seizures buoys optimism. The company is also focusing on geographical diversification of its businesses. Medtronic is highly positive about its foray into the $1 billion standalone CGM market with its Guardian Connect. Overall, in the past three months, Medtronic has outperformed its industry." (8/7/2018)
  • 2. Needham & Company LLC analysts commented, "On 11/8/17, MDT preannounced F2Q18 revenue of $7.050B (up 3% organic Y/Y) vs. consensus of $6.897M. The impact from Hurricane Maria was revised down to ~$60M from ~$250M, which equates to ~1% in quarterly revenue growth and ~$0.03 in non-GAAP EPS. MDT did not update its FY18 revenue or EPS guidance in the press release but did reaffirm F2Q18 non-GAAP EPS growth of flat to slightly up, excluding the ~$0.03 headwind. MDT is scheduled to report full F2Q18 results on 11/21/17 and we intend to wait until then to update our model." (11/9/2017)

Who are some of Medtronic's key competitors?

Who are Medtronic's key executives?

Medtronic's management team includes the folowing people:
  • Mr. Omar S. Ishrak, Chairman & CEO (Age 62)
  • Ms. Karen L. Parkhill, Exec. VP & CFO (Age 53)
  • Mr. Michael J. Coyle, Exec. VP and Group Pres of Cardiac & Vascular Group (Age 56)
  • Mr. Robert J. W. ten Hoedt, Exec. VP and Group Pres, Europe, Middle East & Africa (Age 57)
  • Dr. David Neustaedter, VP, Venture Capital

Has Medtronic been receiving favorable news coverage?

News articles about MDT stock have been trending somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Medtronic earned a news and rumor sentiment score of 0.02 on Accern's scale. They also gave news coverage about the medical technology company an impact score of 46.20 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View Recent Headlines for Medtronic.

Who are Medtronic's major shareholders?

Medtronic's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.24%), Massachusetts Financial Services Co. MA (4.31%), Artisan Partners Limited Partnership (1.73%), Bank of New York Mellon Corp (1.16%), Wells Fargo & Company MN (1.00%) and Dimensional Fund Advisors LP (0.66%). Company insiders that own Medtronic stock include Bradley E Lerman, Bryan C Hanson, Carol A Surface, Hoedt Rob Ten, Hooman Hakami, James T Lenehan, Kendall J Powell, Omar Ishrak, Richard H Anderson, Richard Kuntz and Robert C Pozen. View Institutional Ownership Trends for Medtronic.

Which major investors are selling Medtronic stock?

MDT stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, FMR LLC, Manning & Napier Group LLC, OppenheimerFunds Inc., American Century Companies Inc., Russell Investments Group Ltd., Wells Fargo & Company MN and Caisse DE Depot ET Placement DU Quebec. Company insiders that have sold Medtronic company stock in the last year include Bradley E Lerman, Bryan C Hanson, Carol A Surface, Hooman Hakami, James T Lenehan, Omar Ishrak and Richard Kuntz. View Insider Buying and Selling for Medtronic.

Which major investors are buying Medtronic stock?

MDT stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Bank of New York Mellon Corp, Artisan Partners Limited Partnership, Vontobel Asset Management Inc., OMERS ADMINISTRATION Corp, Waddell & Reed Financial Inc., Zacks Investment Management and Levin Capital Strategies L.P.. Company insiders that have bought Medtronic stock in the last two years include James T Lenehan, Richard H Anderson and Robert C Pozen. View Insider Buying and Selling for Medtronic.

How do I buy shares of Medtronic?

Shares of MDT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Medtronic's stock price today?

One share of MDT stock can currently be purchased for approximately $91.10.

How big of a company is Medtronic?

Medtronic has a market capitalization of $122.46 billion and generates $29.95 billion in revenue each year. The medical technology company earns $3.10 billion in net income (profit) each year or $4.77 on an earnings per share basis. Medtronic employs 86,000 workers across the globe.

How can I contact Medtronic?

Medtronic's mailing address is 20 ON HATCH LOWER HATCH STREET, DUBLIN L2, D02. The medical technology company can be reached via phone at 353-1438-1700 or via email at [email protected]


MarketBeat Community Rating for Medtronic (NYSE MDT)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  988 (Vote Outperform)
Underperform Votes:  647 (Vote Underperform)
Total Votes:  1,635
MarketBeat's community ratings are surveys of what our community members think about Medtronic and other stocks. Vote "Outperform" if you believe MDT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/16/2018 by MarketBeat.com Staff

Featured Article: What does RSI mean?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.